Brief: Liquidia Corp United Therapeutics Filed New Cross-Claims In FDA Suit Against FDA
Sept 17 (Reuters) - Liquidia Corp LQDA.O :
* LIQUIDIA CORP: UNITED THERAPEUTICS FILED NEW CROSS-CLAIMS
IN FDA
SUIT AGAINST FDA, RE-ASSERTING CHALLENGE TO FDA'S ACCEPTANCE OF
CO'S YUTREPIA NDA
* LIQUIDIA- INTENDS TO DEFEND ITS ABILITY TO LAUNCH YUTREPIA
& TO
DEFEND ITSELF AGAINST UNITED'S ALLEGATIONS
Source text for Eikon: ID:n0001104659-24-100714
Further company coverage: LQDA.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug